Key facts
- Trogenix’s last known valuation is $23.7M (Aug 2024).
- It has raised $110.5M; the latest was Early Stage VC ($94.5M) in Oct 2025.
- Notable investors include Meltwind Advisory, IQ Capital Partners, Old College Capital, 4BIO Capital, AIN Ventures — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Trogenix
- ·The full record, as it builds
Funding rounds
No funding rounds for Trogenix are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Trogenix
Developer of a proprietary genetic medicine platform designed to develop precision cancer treatments that selectively target diseased cell states and behaviors. The company offers payloads that reveal cancer to the body's immune system and kill tumor cells, enabling patients with aggressive tumors to receive potentially curative, one-and-done therapies.
- Sector
- Healthcare
- HQ
- Edinburgh, United Kingdom
- Founded
- 2023
- Employees
- 12
- Website
- trogenix.com/
- Ownership
- Privately Held (backing)
Trogenix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Trogenix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Trogenix in its N-PORT filings yet. We sweep new filings monthly.